93 results about "Lipase inhibitors" patented technology

A composition includes α-cyclodextrin and at least one lipase inhibitor. A method for promoting weight loss, inhibiting weight gain, or maintaining weight in a subject in need thereof includes administering α-cyclodextrin and at least one lipase inhibitor to the subject, thereby reducing the bioavailability of ingested fat and reducing the unpleasant gastrointestinal side effects.

The present invention provides fat-binding polymers, which comprise dialkanolamine, dialkanolammonium, aminoalkylpolyol, and ammoniumalkylpolyol pendant groups for subjects in need of fat removal from the gastrointestinal tract, particularly subjects suffering from steatorrhea and / or experiencing side effects from lipase inhibitors. Patients being administered with lipase inhibitors are typically being treated for Type II Diabetes, streatorrhea, and hypertriglyceridemia. The fat binding polymers of this invention are also suitable for use with obese subjects.

A pharmaceutical combination or composition containing a lipase inhibitor, preferably orlistat, and a bile acid sequestrant is useful for treating obesity.

This invention encompasses methods for the treatment and prevention of disorders that include, but are not limited to, eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. The invention further encompasses pharmaceutical compositions and dosage forms which comprise optically pure (-) sibutramine, optionally in combination with a phosphodiesterase inhibitor or a lipase inhibitor.

A stabilized flour, such as stabilized whole grain wheat flour, exhibiting unexpectedly superior extended shelf life and superior biscuit baking functionality, may be produced with or without heating to inhibit lipase by subjecting whole grains or a bran and germ fraction or component to treatment with a lipase inhibitor, such as an acid or green tea extract. Treatment with the lipase inhibitor may be performed during tempering of the whole grains or berries or during hydration of the bran and germ fraction or component.

The invention relates to a method for screening a lipase inhibitor and particularly relates to a method for screening a lipase inhibitor by using a thin-layer chromatography bioautography. The method comprises the following steps of: dissolving a sample to be tested into water and / or an organic solvent, dispensing liquid of the sample to be tested on a thin-layer plate, placing the plate in a developing agent for developing, taking out the plate, and airing the plate for later use; and dipping the obtained thin-layer plate into substrate liquid, dipping the thin-layer plate into lipase liquid after completing solvent evaporation, taking out the thin-layer plate and subjecting the thin-layer plate to an enzymatic reaction at the temperature of 20-40 DEG C, and dipping the thin-layer plate into developing agent liquid for color reaction after completing the enzymatic reaction, thereby obtaining a white and / or brown-yellow spotted result diagram with a purple background. The method for screening the lipase inhibitor has the advantages that complicated instruments and devices are not required, the operation is simple, and the testing cost is low, so that the method is suitable for general laboratories; and the sensitivity and specificity are higher than those of conventional screening methods, and screened results are visual and easily recognized and remembered.

The invention discloses a weight management combination for a lunch and a dinner respectively. The weight management combination is characterized by including a lunch fat-reducing composition and a dinner substitute composition, the lunch fat-reducing composition includes an amylase inhibitor, a lipase inhibitor and a fat burning promoter, the amylase inhibitor includes a white kidney bean extract, the lipase inhibitor includes EGCG, and a lipid absorption conversion inhibitor includes chitosan oligosaccharide; and the dinner substitute composition is prepared from the following components inparts by weight: 25-40 parts of casein, 12-35 parts of a whey protein, 10-15 parts of medium chain triglyceride powder, 20-25 parts of a dietary fiber, 2-5 parts of skim milk powder, 2-5 parts of complex gum and 1-3 parts of decavitamin and mineral substances. According to the weight management combination, the lunch and the dinner are organically combined, collocation is reasonable, pursuit of food can be realized, the purpose of weight loss can also be achieved on the basis of satisfying nutrition demands, and the fast diet weight management combination is provided for a great deal of lose weight people.

The present disclosure provides Diels-Alder adducts of chalcone and prenylphenyl moieties capable of modulating the activity of cannabinoid receptors, and to oligomers of flavan-3-ol capable of modulating fat absorption and storage. Such Diels-Alder adducts of chalcone and prenylphenyl moieties or oligomers of flavan-3-ol can optionally be used in combination with other weight management agents, such as anorectic agents, a lipase inhibitors, other cannabinoid receptor modulators, psychotropic agents, insulin sensitizers, stimulants, or satiety agents, as well as to methods of use thereof such as treating or preventing weight gain or obesity, promoting weight loss, appetite suppression, modifying satiety, or the like.

The present invention provides lipase inhibitory agents comprising a gallotannin or ellagitannin component(s) isolated from teas or Tellima grandiflora as well as foods and beverages and medicines containing said inhibitory agents.The present invention provides lipase inhibitory agents comprising at least one of compounds represented by formula I below:wherein R1, R2 and R3 independently represent H or a gallic acid residue, and R4 and R5 represent H or a gallic acid residue, or R4 and R5 together form an HHDP group represented by the formula below:provided that at least two of R1 to R5 represent a gallic acid residue or when all of R1, R2 and R3 are H, R4 and R5 together form the HHDP group; as well as foods and beverages and medicines containing said lipase inhibitory agents.

This invention provides a pharmaceutical composition comprising a lipase inhibitor; a lipophilic oil absorbent selected from the group consisting of hydrogenated castor oil, hydrogenated vegetable oil, glyceryl behenate, glyceryl palmitostearate and a mixture thereof; and a pharmaceutically acceptable additive, an oral formulation of a lipase inhibitor prepared there from and a method for preparing said formulation. The formulation of the present invention can minimize side effects such as oily spotting, fatty / oily stool, abdominal distension and flatus, and thus it can be advantageously used for preventing or treating obesity and hyperlipaemia.

This invention encompasses methods for the treatment and prevention of disorders that include, but are not limited to, eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. The invention further encompasses pharmaceutical compositions and dosage forms which comprise optically pure (+) sibutramine, optionally in combination with a phosphodiesterase inhibitor or a lipase inhibitor.

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows:wherein Q and Z are defined herein.

The present invention provides lipase inhibitors containing dimers of flavan-3-ols derived from teas as well as foods and beverages and medicines containing said inhibitors. More specifically, the present invention provides lipase inhibitors containing at least one of assamicains represented by the formula:wherein G represents a galloyl group;theasinensins represented by the formula:wherein R1 represents G or H, and R2 represents G; andtheaflavins represented by the formula: